Kangyuan pharmaceutical's exclusive variety of Cistanche total glycoside capsule in the treatment of vascular dementia has obtained new drug certificate

According to the information on the website of the State Food and Drug Administration (CFDA) on July 1, the review status of the exclusive product of Kangyuan pharmaceutical, Cistanche total glycoside capsule and its APIs, is shown as approved pending certification, with the approval numbers of Guoyao Zhun Zi z20143013 and Guoyao Zhun Zi z20143012, respectively Industry insiders pointed out that the approved Cistanche glycoside capsule will enrich the cardiovascular and cerebrovascular product line of Kangyuan pharmaceutical According to the public information, Cistanche glycoside capsule is the exclusive variety purchased by Kangyuan pharmaceutical from Xinghui Tianli (Hangzhou) pharmaceutical last year, which is used to treat vascular dementia, with an effective rate of more than 75% Industry insiders pointed out that there are few similar kinds of traditional Chinese medicine used to treat dementia, and the competition pattern is good after Cistanche glycoside capsule goes on the market; at the same time, Kangyuan pharmaceutical industry is striving to build a cardiovascular and cerebrovascular product line, and Cistanche glycoside capsule will enrich the types of indications covered by the company after going on the market Kangyuan pharmaceutical is mainly engaged in heat clearing and detoxification, orthopedics and gynecology At the end of 2012, the company used ginkgolide injection to expand the field of cardio cerebral vascular, and set cardio cerebral vascular as the main direction of the company's future development In addition to Cistanche total glycoside capsules, the company also has Longxue Tongluo capsule and Tong'an injection which are in the pre IPO preparation stage.